A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma That Has Progressed Following a First L

Status
Active
Cancer Type
Colon/Rectal Cancer
Trial Phase
Phase II
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01479465
Protocol IDs
GS-US-295-0203 (primary)
Study Sponsor
Gilead Sciences

Summary

This randomized study compares the efficacy of GS-6624 versus placebo in combination with FOLFIRI in subjects with colorectal cancer.

Objectives

This randomized Phase 2 study compares the additive efficacy of GS-6624 versus placebo in combination with FOLFIRI in subjects with metastatic KRAS or BRAF mutant colorectal cancer.

Treatment Sites in Georgia


Suburban Hematology-Oncology Associates - Duluth
3855 Pleasant Hill Road
Suite 480
Duluth, GA 30096
www.cancergwinnett.com

Study Coordinator:
Kathy Frank
(678) 533-1567

Doctors:

Christopher T. Hagenstad MD

Suburban Hematology-Oncology Associates - Snellville
1700 Tree Lane Road
Suite 490
Snellville, GA 30078
www.cancergwinnett.com

Study Coordinator:
Kathy Frank
(678) 533-1567

Doctors:

Allan Freedman MD
P. Ravi Sarma MD, FACP
Satvir Singh MD